Merdury Biopharmaceutical Corporation (TPEX:6932)
Taiwan
· Delayed Price · Currency is TWD 8.31
-0.02 (-0.24%)
Apr 29, 2026, 1:57 PM CST
Merdury Biopharmaceutical Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Net Income | -67.23 | -50.57 | -43.82 | -31.25 | -5.31 | Upgrade
|
| Depreciation & Amortization | 11.64 | 7.45 | 4.07 | 2.75 | 0.97 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.62 | - | - | - | - | Upgrade
|
| Stock-Based Compensation | 0.55 | 1.24 | 1.82 | 1.13 | - | Upgrade
|
| Other Operating Activities | 0.06 | 0.46 | 0.29 | -0.02 | - | Upgrade
|
| Change in Accounts Receivable | 0.01 | -0.01 | - | - | - | Upgrade
|
| Change in Accounts Payable | 1.62 | 2.57 | 0.64 | 4.86 | 0.9 | Upgrade
|
| Change in Unearned Revenue | 0.31 | 5.04 | 0.44 | - | - | Upgrade
|
| Change in Other Net Operating Assets | 1.6 | -0.89 | -5.6 | -3.31 | -1.34 | Upgrade
|
| Operating Cash Flow | -50.84 | -34.71 | -42.15 | -25.84 | -4.78 | Upgrade
|
| Capital Expenditures | -6.88 | -10.02 | -12.93 | -68.51 | -6.98 | Upgrade
|
| Sale (Purchase) of Intangibles | -0.42 | -1.08 | -0.65 | -0.14 | -0.53 | Upgrade
|
| Investment in Securities | 52.2 | 121.98 | -176.08 | -108.7 | - | Upgrade
|
| Other Investing Activities | -0.83 | -2.23 | -4.79 | -8.04 | -0.51 | Upgrade
|
| Investing Cash Flow | 44.08 | 108.65 | -194.44 | -185.4 | -8.02 | Upgrade
|
| Long-Term Debt Issued | - | - | - | 41.6 | - | Upgrade
|
| Long-Term Debt Repaid | -4.16 | -1.45 | -1.07 | -0.99 | -0.39 | Upgrade
|
| Net Debt Issued (Repaid) | -4.16 | -1.45 | -1.07 | 40.61 | -0.39 | Upgrade
|
| Issuance of Common Stock | 4.52 | 7.17 | 250 | 200 | 15.97 | Upgrade
|
| Repurchase of Common Stock | -8.56 | -56.24 | - | - | - | Upgrade
|
| Other Financing Activities | - | - | - | - | -0.3 | Upgrade
|
| Financing Cash Flow | -8.21 | -50.52 | 248.93 | 240.61 | 15.28 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.13 | 0.29 | 0.01 | - | - | Upgrade
|
| Net Cash Flow | -14.84 | 23.71 | 12.36 | 29.38 | 2.48 | Upgrade
|
| Free Cash Flow | -57.72 | -44.73 | -55.07 | -94.35 | -11.77 | Upgrade
|
| Free Cash Flow Margin | - | -901.17% | -5331.17% | -3520.60% | - | Upgrade
|
| Free Cash Flow Per Share | -0.14 | -0.11 | -0.14 | -0.25 | -0.04 | Upgrade
|
| Cash Interest Paid | 0.9 | 0.8 | 0.71 | 0.4 | 0.01 | Upgrade
|
| Cash Income Tax Paid | 0.07 | 0.34 | 0.21 | 0.02 | - | Upgrade
|
| Levered Free Cash Flow | -35.91 | -29.87 | -41.24 | -82.81 | -10.3 | Upgrade
|
| Unlevered Free Cash Flow | -35.35 | -29.37 | -40.8 | -82.56 | -10.3 | Upgrade
|
| Change in Working Capital | 3.53 | 6.71 | -4.51 | 1.56 | -0.45 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.